Bibliographic Details
| Title: |
The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development. |
| Authors: |
Moore, Kenneth T., Zannikos, Peter N., Masters, Joanna C., Willmann, Stefan, Shen, Jinshan, Frost, Charles |
| Source: |
Journal of Clinical Pharmacology; Nov2023 Supplement 1, Vol. 63, pS78-S84, 7p |
| Subject Terms: |
OBESITY complications, OBESITY, DRUG efficacy, BODY weight, DRUG development, BODY mass index, ANTIOBESITY agents, COMORBIDITY, PATIENT safety, PHARMACODYNAMICS, DISEASE risk factors |
| Geographic Terms: |
UNITED States |
| Abstract: |
Obesity remains a US national health crisis and a growing concern worldwide. Concerningly, individuals who are obese are at an increased risk for comorbid diseases that include, but are not limited to, hypertension, diabetes, cardiovascular disease, and cancer. Beyond the risk for developing these conditions, obesity may also impact the pharmacological activity of the therapies being used to treat them and other disease states. The pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of therapies, both currently marketed and under clinical development, may be directly impacted by the physiological alterations that occur secondary to the occurrence of chronic excess body weight. The increased prevalence of this disease should not be ignored. Both private and federal institutions involved in drug research and development should consider, as appropriate, a greater inclusion of individuals who are obese in clinical trials throughout the entirety of drug development, and leverage the available PK, PD, safety, and efficacy data to make more informed dosing recommendations. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Clinical Pharmacology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
